NCT06688799View on ClinicalTrials.gov

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions

Autoimmune Diseases

Interventions

DRUG

CD19 CAR-T cells

Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.

Trial Locations (1)

China

RECRUITING

Beijing GoBroad Hospital, Beijing

All Listed Sponsors

lead

Beijing GoBroad Hospital

OTHER